UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1127-17
Program Prior Authorization/Notification
Medication Sovaldi® (sofosbuvir)
P&T Approval Date 2/2014, 4/2014, 5/2014, 8/2014, 2/2015, 8/2015, 2/2016, 2/2017, 2/2018,
2/2019, 2/2020, 2/2021, 2/2022, 2/2023, 5/2023, 5/2024, 5/2025
Effective Date 8/1/2025
1. Background:
Sovaldi® (sofosbuvir) is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor
indicated for the treatment of:
• Adult patients with genotype 1, 2, 3, or 4 chronic HCV infection without cirrhosis or with
compensated cirrhosis as a component of a combination antiviral treatment regimen.
• Pediatric patients 3 years of age and older with genotype 2 or 3 chronic HCV infection without
cirrhosis or with compensated cirrhosis in combination with ribavirin.
2. Coverage Criteriaa:
A. Sovaldi in combination with ribavirin with or without peginterferon alfa:
1. Sovaldi will be approved based on one of the following criteria:
a. All of the following:
(1) Diagnosis of chronic hepatitis C genotype 1 or 4 infection
-AND-
(2) Used in combination with ribavirin
-AND-
(3) One of the following:
(a) Used in combination with peginterferon alfa
-OR-
(b) Both of the following:
1) Patient is ineligible for peginterferon alfa therapy
-AND-
© 2025 UnitedHealthcare Services, Inc.
1
2) Patient has genotype 1 infection
-AND-
(4) Patient has not experienced failure with a previous treatment regimen that
includes Sovaldi
-AND-
(5) Patient is without decompensated liver disease (e.g., Child-Pugh B or C)
-OR-
b. All of the following:
(1) Diagnosis of chronic hepatitis C genotype 2 or 3 infection
-AND-
(2) Used in combination with ribavirin
-AND-
(3) Patient has not experienced failure with a previous treatment regimen that
includes Sovaldi
-OR-
c. All of the following:
(1) Diagnosis of chronic hepatitis C genotype 1, 2, 3, or 4 infection
-AND-
(2) One of the following:
(a) Diagnosis of hepatocellular carcinoma
-OR-
(b) Patient has decompensated liver disease (e.g., Child-Pugh Class B or C)
-AND-
(3) Patient is an active candidate on the waiting list for a liver transplant
-AND-
© 2025 UnitedHealthcare Services, Inc.
2
(4) Used in combination with ribavirin
-AND-
(5) Patient has not experienced failure with a previous treatment regimen that
includes Sovaldi
For GENOTYPES 1 and 4 in combination with peginterferon alfa and ribavirin:
Authorization will be issued for 12 weeks.
For GENOTYPE 1 in combination with ribavirin and ineligible for pegylated
interferon alfa: Authorization will be issued for 24 weeks.
For GENOTYPE 2 in combination with ribavirin: Authorization will be issued for
12 weeks.
For GENOTYPE 3 in combination with ribavirin: Authorization will be issued for
24 weeks.
For GENOTYPES 1, 2, 3, or 4 in combination with ribavirin in patients with
hepatocellular carcinoma OR decompensated liver disease and awaiting liver
transplantation: Authorization will be issued for 48 weeks.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class
• Supply limits, step therapy and medical necessity may be in place.
4. References:
1. Sovaldi [package insert]. Foster City, CA: Gilead Sciences, Inc.; March 2020.
2. American Association for the Study of Liver Diseases and the Infectious Diseases
Society of America. Recommendations for Testing, Managing, and Treating Hepatitis C.
http://www.hcvguidelines.org/full-report-view. Accessed April 10, 2025.
Program Prior Authorization/Notification - Sovaldi™ (sofosbuvir)
Change Control
2/2014 New program.
4/2014 Added criteria for Sovaldi + pegineterferon alfa + ribavirin for genotype
3. Added criteria for Sovaldi + ribavirin for genotype 4. Added criteria
for HCV reinfection after liver transplantation.
5/2014 Added criterion requiring that the patient has not tried a previous
© 2025 UnitedHealthcare Services, Inc.
3
regimen with Sovaldi or has demonstrated intolerance to
Sovaldi/interferon/ribavirin.
Removed symptomatic hepatitis C induced cryoglobulinemia as an
8/2014 option to prove interferon ineligibility. Added criterion requiring that
patient is without decompensated disease throughout, except where
criteria has been revised to allow in decompensated patients awaiting
liver transplant.
12/2014 Administrative correction.
2/2015 Updated background and references. Revised Sovaldi in combination
with Olysio section to reflect revised Olysio prescribing information.
8/2105 Added criteria for combination therapy with Daklinza (daclatasavir).
2/2016 Annual review with no clinical changes. Updated references.
2/2017 Annual review. Removal of Sovaldi/ribavirin combination for post
transplant therapy in genotypes 1, 3, and 4 as no longer recommended
by guidelines. Updated approval duration to 24 weeks for genotype 2
post liver transplant. Added genotype 1 to criteria for combination
therapy with Daklinza (daclatasavir).
2/2018 Annual review with no change to coverage criteria. Updated references.
2/2019 Removed use with Olysio (simeprevir) to reflect market withdrawal.
Updated criteria to remove reinfection after liver transplant for
genotype 2. Updated approval durations.
2/2020 Annual review. Clarification to genotype 1 or 4 length of therapy with
ribavirin +/- peginterferon. Removed criteria for use with Daklinza, as
Daklinza is now off the market. Updated background and references.
2/2021 Annual review. No changes to clinical coverage criteria. Background
and references updated.
2/2022 Annual review. No changes to clinical coverage criteria. References
updated.
2/2023 Annual review without changes to clinical coverage criteria. Added
state mandate and updated references.
5/2023 Simplified peginterferon eligibility requirements. Updated references.
5/2024 Annual review. Updated background and references.
5/2025 Annual review without changes to coverage criteria. Updated
references.
© 2025 UnitedHealthcare Services, Inc.
4